ASCO 2024 . IMFINZI ( DURVALUMAB BY ASTRAZÉNECA ) Significantly Improved Overall Survival And Progression-Free Survival For Patients With Limited-Stage Small Cell Lung Cancer In ADRIATIC Phase III Trial .